Harnessing the Power of Electronic Health Records and Genomics for Drug Discovery

Annu Rev Pharmacol Toxicol. 2023 Jan 20;63:65-76. doi: 10.1146/annurev-pharmtox-051421-111324.ABSTRACTA long-standing recognition that information from human genetics studies has the potential to accelerate drug discovery has led to decades of research on how to leverage genetic and phenotypic information for drug discovery. Established simple and advanced statistical methods that allow the simultaneous analysis of genotype and clinical phenotype data by genome- and phenome-wide analyses, colocalization analyses with quantitative trait loci data from transcriptomics and proteomics data sets from different tissues, and Mendelian randomization are essential tools for drug development in the postgenomic era. Numerous studies have demonstrated how genomic data provide opportunities for the identification of new drug targets, the repurposing of drugs, and drug safety analyses. With an increase in the number of biobanks that enable linking in-depth omics data with rich repositories of phenotypic traits via electronic health records, more powerful ways for the evaluation and validation of drug targets will continue to expand across different disciplines of clinical research.PMID:36662581 | DOI:10.1146/annurev-pharmtox-051421-111324

Source: Annual Review of Pharmacology and Toxicology - January 20, 2023 Category: Drugs & Pharmacology Authors: Kristi Krebs Lili Milani Source Type: research